Clinical trialRSSYesterday
A grandmother shares how a small change in how her grandson's condition was measured helped him qualify for a Duchenne muscular dystrophy (DMD) treatment trial. Researchers adjusted the scoring system by 19 points, which gave him a second chance to participate in the study. This story highlights how trial eligibility rules can sometimes be adjusted to help more patients access new treatments.
WHY IT MATTERSIf your child with DMD has been told they don't qualify for a trial, this story shows that eligibility criteria can sometimes be reconsidered or adjusted—it's worth asking your doctor whether similar flexibility might apply to your situation.
Clinical trialRSSYesterday
A new treatment called Roctavian was given as a single injection to men with severe hemophilia A (a bleeding disorder). Seven years later, most patients had fewer bleeding episodes and needed less preventive medicine. This suggests the treatment's benefits can last for many years.
WHY IT MATTERSIf you have severe hemophilia A, Roctavian could mean switching from frequent infusions or injections to a single treatment that protects you from bleeds for years.
Drug approvalOPENFDAYesterday
The FDA has approved a new drug made by Merck Sharp and Dohme LLC. However, the specific name of the drug and the disease it treats are not listed in this announcement. Patients and doctors will need to find more details from official FDA sources to learn what condition this drug is for and whether it might help them.
WHY IT MATTERSWithout knowing the specific drug name and indication, we cannot determine the relevance to any particular patient population — this announcement lacks critical details needed to assess impact.
ResearchRSS3 days ago
Scientists discovered that blocking a protein pathway called JNK in the body may help treat spinal muscular atrophy (SMA), a disease that weakens muscles. In mice with severe SMA, blocking this pathway reduced how bad the disease got and helped the mice live longer. This new approach could work by itself or combined with medicines that are already approved for SMA.
WHY IT MATTERSIf this JNK pathway blocking approach moves to human trials, it could offer SMA patients a new treatment option, potentially as a combination therapy with existing approved drugs like nusinersen or onasemnogene abeparvovec.
AdvocacyRSS3 days ago
A patient-led nonprofit called The Speak Foundation has created a network of specialized clinics called LGMD Centers of Excellence to help people with limb-girdle muscular dystrophy (LGMD), a rare muscle disease. This new network aims to solve a major problem: patients with LGMD have had trouble getting consistent care and doctors have struggled to develop new treatments because the patient population is very small and spread out.
WHY IT MATTERSThis coordinated clinic network could help LGMD patients access specialized care in one place and speed up the development of new treatments by making it easier for researchers to find and study patients.
AdvocacyRSS3 days ago
Three organizations that work with facioscapulohumeral muscular dystrophy (FSHD) patients are joining together to make clinical trials better. FSHD is a rare muscle disease that causes weakness in the face, shoulders, and upper arms. This partnership wants to improve how these trials are designed so they can test new treatments more effectively.
WHY IT MATTERSBetter-designed clinical trials mean faster progress toward treatments for FSHD, and patient input through the FSHD Society ensures trials are structured in ways that actually work for people living with the disease.
Clinical trialCLINICALTRIALSApr 17
Researchers are testing a new treatment called IFx-Hu2.0 combined with a cancer drug called pembrolizumab for people with Merkel cell carcinoma, a rare and aggressive skin cancer. In this study, some patients will receive the new treatment while others receive a placebo (fake treatment) to see which works better. The trial is looking for 118 adults to participate and is currently accepting new patients.
WHY IT MATTERSThis is the first Phase 2/3 trial testing IFx-Hu2.0 as an add-on therapy for Merkel cell carcinoma, offering checkpoint inhibitor-naïve patients a potential new treatment option beyond standard pembrolizumab alone.
ResearchBIORXIVApr 17
Scientists created OpenScientist, a new artificial intelligence tool that can help researchers discover medical breakthroughs faster. This AI assistant can read through lots of medical information, analyze data, and put together what it learns — tasks that normally take human scientists a long time. The goal is to speed up finding new treatments and understanding diseases better.
WHY IT MATTERSThis AI tool could help researchers discover new treatments and understand rare diseases more quickly by automating time-consuming research tasks, potentially leading to faster development of therapies for patients with rare conditions.
PolicyRSSApr 16
The FDA is inviting companies that make testosterone replacement therapy drugs to apply for approval of a new use: treating low sex drive in men with a specific condition called idiopathic hypogonadism (when the body doesn't make enough testosterone for unknown reasons). This is an early step that could lead to new treatment options for men with this condition.
WHY IT MATTERSMen with idiopathic hypogonadism who experience low libido may soon have an FDA-approved treatment option specifically designed for this symptom, rather than relying on off-label use of existing testosterone therapies.
Clinical trialUNITERAREApr 15
Researchers are looking for patients with a specific type of blood cancer called Philadelphia chromosome positive acute lymphoblastic leukemia to test a new treatment combination. The treatment uses chemotherapy drugs (EPOCH), sometimes combined with rituximab (a protein therapy), plus a targeted drug called ponatinib. This is a Phase 2 trial, meaning it's testing whether the treatment works and is safe in a larger group of patients.
WHY IT MATTERSThis trial is now actively recruiting patients with newly-diagnosed Ph+ ALL/lymphoma and offers access to ponatinib, a third-generation tyrosine kinase inhibitor that may improve outcomes for this aggressive blood cancer.
🔴 BreakingDrug approvalOPENFDAApr 4
The FDA has approved a new drug called FOUNDAYO (orforglipron), made by Eli Lilly. This approval means the medication is now available for patients to use. The drug was officially approved on April 1, 2026.
WHY IT MATTERSWithout information about which rare disease FOUNDAYO treats, we cannot specify the patient impact — the article lacks details about the condition it addresses or which patients are eligible.
Clinical trialUNITERAREApr 3
Researchers are testing a new treatment approach for elderly patients with a type of blood cancer (MDS or AML) that has come back or stopped responding to previous treatments. The study uses a combination of chemotherapy drugs followed by a stem cell transplant from a donor to try to help patients recover. This trial is now actively looking for patients to participate.
WHY IT MATTERSThis trial offers elderly patients with relapsed or refractory MDS/AML a potentially less toxic conditioning regimen before stem cell transplant — cladribine-bridged LABU may improve tolerability compared to standard high-dose approaches in this vulnerable population.
Clinical trialUNITERAREApr 3
Researchers are looking for patients with a type of blood cancer called acute lymphoblastic leukemia (ALL) to test a new treatment combination. The study will test whether adding a drug called JZP458 to standard chemotherapy works better than chemotherapy alone. This trial is just starting and will recruit patients beginning in April 2026.
WHY IT MATTERSThis Phase 2 trial is now actively recruiting newly diagnosed ALL patients without the Philadelphia chromosome, offering access to an investigational asparaginase formulation (JZP458) that may have improved tolerability compared to standard asparaginase.
Clinical trialUNITERAREApr 3
Triple Hair Inc is recruiting patients for a Phase 3 clinical trial testing a new treatment called TH07 for androgenic alopecia, commonly known as male or female pattern baldness. This is a large-scale study to confirm whether TH07 works better than current treatments. If you have pattern hair loss, you may be eligible to join and help test this potential new therapy.
WHY IT MATTERSThis Phase 3 trial is actively recruiting now, meaning if you have androgenic alopecia, you could potentially enroll and access an investigational treatment while contributing to evidence that could lead to FDA approval.
Clinical trialUNITERAREApr 3
Researchers at New York State Institute for Basic Research are testing a new treatment called transcranial direct current stimulation (tDCS) in children with autism. This treatment uses mild electrical currents applied to the scalp to potentially help with autism symptoms. The study is now accepting children to participate and will begin in April 2026.
WHY IT MATTERSThis trial offers families with autistic children a chance to explore a non-medication brain stimulation approach that may help with core autism symptoms, with enrollment actively opening at a major research institution.
🔴 BreakingDrug approvalRSSApr 3
The FDA has approved a new drug called Avlayah to treat Hunter syndrome, a rare genetic disease that affects the brain and nervous system. Hunter syndrome happens when the body can't break down certain substances properly, causing serious health problems over time. This approval means patients with Hunter syndrome now have a new treatment option available to help manage the neurologic symptoms of their condition.
WHY IT MATTERSThis is the first FDA approval of Avlayah specifically for the neurologic manifestations of Hunter syndrome, offering patients a new therapeutic option for managing brain and nervous system symptoms that were previously difficult to treat.
🔴 BreakingDrug approvalRSSApr 3
The FDA approved a new drug called Foundayo (orforglipron) on a special fast-track program called the National Priority Voucher program. This is the fifth drug approved through this program, which helps speed up approval for medicines that address important health needs. The program is designed to get helpful new treatments to patients faster.
WHY IT MATTERSThis approval demonstrates the National Priority Voucher program is working to bring new treatment options to patients with rare diseases more quickly than the standard FDA review process.
🔴 BreakingDrug approvalRSSApr 3
The FDA has approved a new treatment called Kresladi for a rare immune system disorder called Leukocyte Adhesion Deficiency Type I (LAD-I). This treatment works by using gene therapy, which means it fixes the faulty gene that causes the disease. This is the first gene therapy approved for this specific condition, giving patients with LAD-I a new treatment option.
WHY IT MATTERSPatients with severe LAD-I now have access to the first FDA-approved gene therapy for their condition, which could potentially offer a cure rather than just managing symptoms.
🔴 BreakingDrug approvalOPENFDAApr 3
The FDA has approved a new drug called FLAVALTA, which contains lidocaine and epinephrine. Lidocaine is a numbing medication, and epinephrine helps control bleeding. This approval means the drug is now available for patients to use, though the specific medical condition it treats is not detailed in this announcement.
WHY IT MATTERSThis approval makes a new numbing and bleeding-control medication available to patients who need it, though the specific rare disease indication requires clarification from your doctor or the full prescribing information.
Drug approvalOPENFDAApr 3
The FDA has approved a new drug made by Baxter Healthcare Corporation. However, the specific name of the drug and what disease it treats are not listed in this announcement. Patients and doctors will need to find more details from official FDA sources to learn what this medication does and who it might help.
WHY IT MATTERSWithout knowing the drug name or indication, we cannot determine specific relevance to any patient population — this announcement lacks critical details needed to assess impact.